CDER Closes Out 2008 With 24 Novel Approvals, But Few Are First In Class
Executive Summary
FDA's second-half surge in approvals made 2008 the agency's best year for NME approval counts since 2004, but the relatively high number is generated by a slate of products with a relatively low level of innovation
You may also be interested in...
Biologics Reached Record Share Of Novel Approvals In 2009
The pharmaceutical industry's strategy of looking to biologics as a source of innovation is clearly demonstrated in FDA's novel approvals in 2009
Biologics Reached Record Share Of Novel Approvals In 2009
The pharmaceutical industry’s strategy of looking to biologics as a source of innovation is clearly demonstrated in FDA’s novel approvals in 2009.
Biologics Reached Record Share Of Novel Approvals In 2009
The pharmaceutical industry’s strategy of looking to biologics as a source of innovation is clearly demonstrated in FDA’s novel approvals in 2009.